SCHEMBL5045409

SCHEMBL5045409

COC(=O)COc1cccc(F)c1C(OC)C(=O)NCc1ccc(C#N)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.42
JAK2 O60674 1/20 0.42
HIF1A Q16665 1/20 0.41
PKM P14618 1/20 0.40
AKR1B1 P15121 1/20 0.39
ALDH1A1 P00352 1/20 0.38
NPC1 O15118 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
VNN1 O95497 2/20 0.37
MAPK1 P28482 1/20 0.37
CARM1 Q86X55 2/20 0.37
PRMT6 Q96LA8 2/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
FAAH O00519 1/20 0.37
SLC1A3 P43003 1/20 0.37
SLC1A2 P43004 1/20 0.37
AR P10275 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5042657 0.91 HIF1A (0.41) HIF1APKMAKR1B1ALDH1A1MEN1
SCHEMBL5040796 0.89 PKM (0.41) HIF1APKMALDH1A1VNN1CARM1
SCHEMBL5042636 0.89 HIF1A (0.46) HIF1APKMALDH1A1HTTMAPK1
SCHEMBL5042640 0.89 HIF1A (0.46) HIF1APKMALDH1A1HTTMAPK1
SCHEMBL5041550 0.88 PKM (0.48) HIF1APKMALDH1A1VNN1CARM1
SCHEMBL5041552 0.88 PKM (0.48) HIF1APKMALDH1A1VNN1CARM1
SCHEMBL5042039 0.84 PKM (0.45) HIF1APKMALDH1A1CARM1PRMT6
SCHEMBL5042034 0.84 PKM (0.45) HIF1APKMALDH1A1CARM1PRMT6
SCHEMBL5043333 0.82 PKM (0.41) HIF1APKMALDH1A1MAPTCARM1
Acetic Acid SCHEMBL5042397 0.81 KDM4E (0.42) KDM4EJAK2PKMALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives THERAPHARM GMBH (CH) 2008-12-18 US disclosed
EP-1567498-B1 MANDELIC ACID DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-01-23 EP disclosed
US-7129238-B2 Mandelic acid derivatives HOFFMANN-LA ROCHE INC. (US) 2006-10-31 US disclosed
EP-1567498-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2005-08-31 EP disclosed
US-20040122057-A1 Novel mandelic acid derivatives HOFFMANN-LA ROCHE INC. 2004-06-24 US disclosed
WO-2004048335-A2 MANDELIC ACID DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122057-A1 Novel mandelic acid derivatives F7, F11, F9 KDM4E 2563/4885JAK2 2628/4885HIF1A 251/4885
US-20080312430-A1 Method of Preparing or Synthesizing Polyazamacrocycle Derivatives POLI, PARP1, DHPS KDM4E 2936/4885JAK2 1586/4885HIF1A 1929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.